FDA Posts ICH Q4B Analytical Guidances - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Posts ICH Q4B Analytical Guidances


ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration (Rockville, MD, www.fda.gov) has published a draft guidance, Q4B Regulatory Acceptance of Analytical Procedures and/or Acceptance Criteria (RAAPAC), available online at http://www.fda.gov/cder/guidance/7386dft.htm. The guidance describes the  International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH, www.ich.org) Q4B draft standard (as revised in June), outlining the procedure for "acceptance by regulatory authorities of pharmacopoeial" standards for APAC (analytical procedures and/or acceptance criteria).  (ICH's  Q4 activities focus on harmonizing the requirements of the world's pharmacopoeias.)

At the same time, FDA published the first specific draft guidance under the RAAPAC procedure, Annex 1:  Residue on Ignition/Sulphated Ash General Chapter Analytical Procedures and/or Acceptance Criteria (APAC) (http://www.fda.gov/cder/guidance/7387dft.htm).

The guidance describes the reconciliation (via specification of sample size and a caveat on test-furnace calibration) of US Pharmacopeia, European Pharmacopoeia, and Japanese Pharmacopoeia testing procedures for residual ash, an index of the inorganic impurities in an organic sample.

The eight-page guidance and four-page annex were posted jointly by the Center for Drug Evaluation and Research and the Center for Biologics Evaluation and Research.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
27%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
32%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here